RESUMEN
We have studied the effects of four doses of atenolol in 11 patients with stable angina pectoris using a symptom-limited exercise test and angina diaries. The doses 100 mg twice daily and 50 mg, 100 mg and 200 mg once daily were given double-blind and randomised within patients following run-in on placebo. Measurements were made 12 hours after the last twice daily dose and 24 hours after the last once daily dose. Exercise tolerance was improved by 40-74% and exercise duration before the onset of angina by 61-94% (P less than 0.01). Maximal heart rate was reduced further by a total daily dose of 200 mg than by lower doses, but no extra benefit was derived by giving the drug twice daily. The largest increase in exercise tolerance was obtained during treatment with 50 mg once daily. Atenolol was shown to be an effective anti-anginal agent when given once daily, and there were no major differences between the doses studied.
Asunto(s)
Angina de Pecho/tratamiento farmacológico , Atenolol/administración & dosificación , Propanolaminas/administración & dosificación , Adulto , Anciano , Angina de Pecho/fisiopatología , Ensayos Clínicos como Asunto , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Prueba de Esfuerzo , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Distribución Aleatoria , Factores de TiempoAsunto(s)
Antagonistas Adrenérgicos beta/uso terapéutico , Cardiomiopatías/tratamiento farmacológico , Etanolaminas/uso terapéutico , Propranolol/uso terapéutico , Adolescente , Antagonistas Adrenérgicos beta/administración & dosificación , Presión Sanguínea/efectos de los fármacos , Cateterismo Cardíaco , Gasto Cardíaco/efectos de los fármacos , Estudios de Evaluación como Asunto , Femenino , Insuficiencia Cardíaca/fisiopatología , Frecuencia Cardíaca/efectos de los fármacos , Ventrículos Cardíacos/fisiopatología , Humanos , Inyecciones Intravenosas , Isoproterenol/uso terapéutico , Persona de Mediana Edad , Esfuerzo FísicoRESUMEN
1 The effects of atenolol (50 mg and 100 mg) and oxprenolol (80 mg) on respiratory function were studied in ten patients with angina pectoris or hypertension complicated by chronic airways obstruction. 2 In patients with "fixed" airways obstruction, neither atenolol nor exprenolol significantly affected airways resistance. 3 In patients with "labile" airways obstruction, atenolol did not produce a significant increase in airways obstruction, whereas oxprenolol did. 4 Following isoprenaline challenge (1500 microgram by inhalation), atenolol permitted full bronchodilatation, whereas oxprenolol almost completely blocked the action of isoprenaline. 5 Partial agonist activity appears to be of less clinical importance than cardioselectivity.